Abemaciclib in combination with nonsteroidal aromatase inhibitors (NSAIs) is approved as first‐line therapy for postmenopausal women with HR‐positive, HER2‐negative advanced breast cancer based on positive PFS results from the MONARCH 3 trial. The gene discussed is CYP19A1; the disease is breast carcinoma.